Next Article in Journal
Peptide-Based Vaccines for Neurodegenerative Diseases: Recent Endeavors and Future Perspectives
Next Article in Special Issue
COVID-19 Vaccine Boosters: The Good, the Bad, and the Ugly
Previous Article in Journal
Changes in Behaviors and Attitudes in Response to COVID-19 Pandemic and Vaccination in Healthcare Workers and University Students in Italy
Previous Article in Special Issue
Assessment of Anti-SARS-CoV-2 Antibodies Post-Coronavac Vaccination in the Amazon Region of Brazil
 
 
Article

Humoral Response after Vaccination with Half-Dose of BNT162b2 in Subjects under 55 Years of Age

1
Invicta Research and Development Center, 81-740 Sopot, Poland
2
Department of Obstetrics and Gynecology Nursing, Medical University of Gdansk, 80-210 Gdansk, Poland
3
The Center of Postgraduate Medical Education, 1st Department of Obstetrics and Gynecology, University of Gdansk, 01-004 Warsaw, Poland
4
Department of Human Histology and Embryology, Medical Faculty, Collegium Medicum, University of Warmia and Mazury in Olsztyn, 10-082 Olsztyn, Poland
5
Department of Gamete and Embryo Biology, Institute of Animal Reproduction and Food Research, Polish Academy of Sciences, 10-748 Olsztyn, Poland
6
Laboratory of Recombinant Vaccines, Intercollegiate Faculty of Biotechnology, University of Gdansk, 80-307 Gdansk, Poland
*
Authors to whom correspondence should be addressed.
Academic Editors: Ralph A. Tripp, Steven B. Bradfute and Scott Anthony
Vaccines 2021, 9(11), 1277; https://doi.org/10.3390/vaccines9111277
Received: 15 September 2021 / Revised: 26 October 2021 / Accepted: 31 October 2021 / Published: 4 November 2021
(This article belongs to the Collection COVID-19 Vaccines and Vaccination)
In the context of the ongoing COVID-19 pandemic, using a half-dose schedule vaccination can help to return to normalcy in a cost-efficient manner, which is especially important for low and middle-income countries. We undertook a study to confirm that in adults up to 55 years old, the humoral response to the half-dose (15 µg, 35 participants between 18 and 55 years old) and to the recommended dose (30 µg, 155 participants) in the two-dose three-week interval schedule would be comparable. Antibody levels were measured by the Elecsys Anti-SARS-CoV-2 S assay (Roche Diagnostics, upper detection limit: 2570 BAU/mL) on the day of dose 2 of the vaccine and then 8–10 days later to assess peak response to dose 2. The difference in proportions between the participants who did and did not exceed the upper detection limit 8–10 days after dose 2 was not statistically significant (p = 0.152). We suggest that a half-dose schedule can help to achieve widespread vaccination coverage more quickly and cheaply. View Full-Text
Keywords: SARS-CoV-2; COVID-19; mRNA vaccine SARS-CoV-2; COVID-19; mRNA vaccine
Show Figures

Figure 1

MDPI and ACS Style

Lukaszuk, K.; Podolak, A.; Jakiel, G.; Kiewisz, J.; Woclawek-Potocka, I.; Lukaszuk, A.; Rabalski, L. Humoral Response after Vaccination with Half-Dose of BNT162b2 in Subjects under 55 Years of Age. Vaccines 2021, 9, 1277. https://doi.org/10.3390/vaccines9111277

AMA Style

Lukaszuk K, Podolak A, Jakiel G, Kiewisz J, Woclawek-Potocka I, Lukaszuk A, Rabalski L. Humoral Response after Vaccination with Half-Dose of BNT162b2 in Subjects under 55 Years of Age. Vaccines. 2021; 9(11):1277. https://doi.org/10.3390/vaccines9111277

Chicago/Turabian Style

Lukaszuk, Krzysztof, Amira Podolak, Grzegorz Jakiel, Jolanta Kiewisz, Izabela Woclawek-Potocka, Aron Lukaszuk, and Lukasz Rabalski. 2021. "Humoral Response after Vaccination with Half-Dose of BNT162b2 in Subjects under 55 Years of Age" Vaccines 9, no. 11: 1277. https://doi.org/10.3390/vaccines9111277

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop